By results of implementation of extensive medicine coverage/essential medicine coverage program in Russia in 2008, AO “Pharm-Sintez” was the only national company to get to the 24th place in the TOP 25 corporation by sales volume in the sector in 2008. Increase in sales for the company, announced phase-out of imported drugs as one of the key strategic objectives, in 2008 reached 345%. Maximal increase in sales in the EDC sector in 2008 among national brands of AO “Pharm-Sintez” saw following products: Octreotide-depo – 1763%; Rezorba (Resorba Zoledronic acid) - 1021%.
